We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
-6.99%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.71B
AUM Growth
-$39.6M
Cap. Flow
+$72.3M
Cap. Flow %
4.23%
Top 10 Hldgs %
57.63%
Holding
146
New
23
Increased
28
Reduced
39
Closed
16

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$28.5M
2
ESTA icon
Establishment Labs
ESTA
+$27.8M
3
PTON icon
Peloton Interactive
PTON
+$16.6M
4
SVRA icon
Savara
SVRA
+$15.3M
5
OPTN
OptiNose
OPTN
+$12.2M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$25.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$17.5M
3
RDVT icon
Red Violet
RDVT
+$13.4M
4
DYN icon
Dyne Therapeutics
DYN
+$12.4M
5
GDEN
Golden Entertainment
GDEN
+$9.92M

Sector Composition

Rank Sector Weight
1 Healthcare 39.62%
2 Consumer Discretionary 7%
3 Financials 3.63%
4 Communication Services 3.53%
5 Technology 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
126
DELISTED
Aptose Biosciences, Inc.
APTO
$58.7K ﹤0.01%
2,578
-373
-13% -$12.7K
GFAIW icon
127
Guardforce AI Warrant
GFAIW
$90K
$30.1K ﹤0.01%
154,205
– –
RNLX
128
DELISTED
Renalytix plc American Depositary Shares
RNLX
$27.2K ﹤0.01%
117,644
– –
TCBPW
129
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
$2.94K ﹤0.01%
235,294
– –
AGS
130
DELISTED
PlayAGS
AGS
– –
-566,588
Closed -$5.09M
ARHS icon
131
Arhaus
ARHS
$1.34B
– –
-1
Closed -$15
JBIO
132
Jade Biosciences
JBIO
$1.32B
– –
-2,605
Closed -$2.7M
COST icon
133
PUT
Costco
COST
$423B
– –
-70,000
Closed -$51.3M
CUE icon
134
Cue Biopharma
CUE
$110M
– –
-890
Closed -$50.4K
DYN icon
135
Dyne Therapeutics
DYN
$4.95B
– –
-435,256
Closed -$12.4M
ESTA icon
136
CALL
Establishment Labs
ESTA
$2.21B
– –
-550,000
Closed -$28M
GDEN
137
DELISTED
Golden Entertainment
GDEN
– –
-269,267
Closed -$9.92M
IYR icon
138
PUT
iShares US Real Estate ETF
IYR
$4.52B
– –
-300,000
Closed -$27M
LYRA
139
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-56,420
Closed -$17.5M
NAMS icon
140
NewAmsterdam Pharma
NAMS
$3.34B
– –
-175,000
Closed -$4.14M
PLCE icon
141
Children's Place
PLCE
$58.3M
– –
-100,000
Closed -$1.15M
TARS icon
142
Tarsus Pharmaceuticals
TARS
$2.97B
– –
-150,321
Closed -$5.46M
HURA
143
TuHURA Biosciences
HURA
$137M
– –
-365
Closed -$1.28K
MTTR
144
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
– –
-548,376
Closed -$1.24M
GMDA
145
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-800,000
Closed -$28.9K
2 3 4 5
6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Nantahala Capital Management held 146 positions worth $1.71B, down 2.3% from $1.75B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Nantahala Capital Management deployed $72.3M of net new capital in Q2 2024, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was The Bancorp: 337,846 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Pathward Financial, an estimated $25.3M trimmed.

  • Nantahala Capital Management's largest Q2 2024 buy was The Bancorp: 337,846 shares worth $12.8M.
  • Nantahala Capital Management added most to Soleno Therapeutics in Q2 2024, an estimated $28.5M increase.
  • Nantahala Capital Management's biggest Q2 2024 reduction was Pathward Financial, cutting an estimated $25.3M.
  • Nantahala Capital Management fully exited LYRA THERAPEUTICS INC in Q2 2024, selling an estimated $17.5M.
  • Nantahala Capital Management's ten largest holdings make up 58% of its $1.71B portfolio in Q2 2024.
  • Nantahala Capital Management opened 23 new positions and closed 16 in Q2 2024.
  • Nantahala Capital Management's portfolio value fell 2.3% quarter-over-quarter to $1.71B.

Based on Nantahala Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.